ArticleKidney international reports2025
Proteomic Analysis of Circulating IgA1-Containing Immune Complexes in Patients with IgA Nephropathy.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers.Advances in therapy · 2026Article
- Plasma Proteomics in IgA Nephropathy: From Circulating Biomarkers to Molecular Endotypes.Cells · 2026Review
- Inhibition of p65 NF-κB enhances production of galactose-deficient IgA1 through suppression ofbioRxiv : the preprint server for biology · 2026Article
- Quantitative Proteomics: Recent Advances in Glomerular Disease and Nephrotic Syndrome.Glomerular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Introduction: IgA1-containing immune complexes (IgA1-IC) consisting of galactose-deficient IgA1 (Gal-deficient IgA1) and IgG autoantibodies are central to the pathogenesis of IgA nephropathy (IgAN). These IgA1-IC form in circulation, and additional proteins may be added before the deposition in the glomeruli. However, the composition of these circulating IgA1-IC is not fully understood. To address this gap in knowledge, we developed a novel proteomic workflow. Methods: IgA1-IC from sera of patients with IgAN and healthy controls (HCs) were isolated by lectin-affinity chromatography followed by size-exclusion chromatography (SEC). IgA1 yield and molecular integrity were assessed by enzyme-linked immunosorbent assay and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After proteolytic digestion, IgA1-IC samples were analyzed by using liquid chromatography-mass spectrometry (LC-MS). LC-MS results were analyzed by label-free quantification (LFQ) to identify proteins in IgA1-IC of patients with IgAN versus HCs versus proteomes of monomeric IgA1 (mIgA1) and polymeric IgA1 (pIgA1). Results: We ascertained that 22 proteins were more abundant in the chromatographic fractions with IgA1-IC from patients with IgAN compared with similar fractions from HCs and other, uncomplexed IgA1 molecular forms. These proteins encompassed immunoglobulins, several complement proteins, including those with regulatory functions, and apolipoproteins. In addition, the identified proteins were validated by use of orthogonal serum preparation and analysis of previously published proteomics data. Conclusion: Our new workflow better characterized the serum IgA1-IC of patients with IgAN by identifying proteins with elevated abundance in IgA1-IC in patients with IgAN, including complement components and apolipoproteins. Complement proteins identified in this study indicate that the alternative and lectin pathways are involved, but not the classical pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.